An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).

Daniel Lee,Haley Gittleman,Chana Weinstock,Daniel L. Suzman,Erik Bloomquist,Sundeep Agrawal,Michael Holman Brave,Jamie Renee Brewer,Harpreet Singh,Shenghui Tang,Richard Pazdur,Julia A. Beaver,Amna Ibrahim,Laleh Amiri-Kordestani

An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).

2021

Daniel Lee
Haley Gittleman
Chana Weinstock
Daniel L. Suzman
Erik Bloomquist
Sundeep Agrawal
Michael Holman Brave
Jamie Renee Brewer
Harpreet Singh
Shenghui Tang
Richard Pazdur
Julia A. Beaver
Amna Ibrahim
Laleh Amiri-Kordestani

4559Background: The International Metastatic RCC Database Consortium (IMDC) risk model was developed for prognosis of patients with mRCC treated with vascular endothelial growth factor (VEGF)-targe...

Keywords:

combined treatment
Internal medicine
pooled analysis
Medicine
Oncology
Renal cell carcinoma
risk groups
Vascular endothelial growth factor
VEGF receptors
risk model

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations